H Schuitemaker
#133,168
Most Influential Person Now
Researcher
H Schuitemaker's AcademicInfluence.com Rankings
Download Badge
Physics
H Schuitemaker's Degrees
- PhD Physics University of Amsterdam
- Masters Physics University of Amsterdam
- Bachelors Physics University of Amsterdam
Why Is H Schuitemaker Influential?
(Suggest an Edit or Addition)H Schuitemaker's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 (2021) (1283)
- Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population (1992) (1146)
- The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation (2010) (1129)
- A new classification for HIV-1 (1998) (899)
- Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule (1992) (829)
- Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine (2021) (813)
- Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics (1995) (737)
- Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques (2020) (736)
- Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. (1994) (549)
- Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies (2012) (499)
- Vaccine Protection Against Acquisition of Neutralization-Resistant SIV Challenges in Rhesus Monkeys (2011) (481)
- T cell depletion in HIV-1 infection: how CD4+ T cells go out of stock (2000) (437)
- Monocytotropic human immunodeficiency virus type 1 (HIV-1) variants detectable in all stages of HIV-1 infection lack T-cell line tropism and syncytium-inducing ability in primary T-cell culture (1991) (339)
- Protective Efficacy of a Global HIV-1 Mosaic Vaccine against Heterologous SHIV Challenges in Rhesus Monkeys (2013) (312)
- Association between CCR5 Genotype and the Clinical Course of HIV-1 Infection (1997) (309)
- Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes (2015) (301)
- In vivo HIV-1 infection of CD45RA(+)CD4(+) T cells is established primarily by syncytium-inducing variants and correlates with the rate of CD4(+) T cell decline. (2000) (297)
- Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology (2015) (286)
- Effects of CCR5- 32, CCR2-64I, and SDF-1 3A Alleles on HIV-1 Disease Progression: An International Meta-Analysis of Individual-Patient Data (2001) (282)
- Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys (2015) (275)
- Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters (2020) (257)
- Relation of phenotype evolution of HIV-1 to envelope V2 configuration. (1993) (252)
- Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. (1999) (233)
- Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans (2021) (232)
- Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial. (2016) (232)
- Ad26/MVA Therapeutic Vaccination with TLR7 Stimulation in SIV-Infected Rhesus Monkeys (2016) (222)
- A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism (2015) (216)
- Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19) (2018) (214)
- Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19. (2021) (211)
- Autologous Neutralizing Humoral Immunity and Evolution of the Viral Envelope in the Course of Subtype B Human Immunodeficiency Virus Type 1 Infection (2008) (206)
- The role of a stromal cell‐derived factor‐1 chemokine gene variant in the clinical course of HIV‐1 infection (1998) (205)
- T-cell dysfunction in HIV infection: anergy due to defective antigen-presenting cell function? (1993) (202)
- The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course? (1994) (193)
- Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses (2020) (193)
- Proliferation-dependent HIV-1 infection of monocytes occurs during differentiation into macrophages. (1992) (188)
- Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. (2010) (184)
- Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study (1998) (173)
- Prospects for a safe COVID-19 vaccine (2020) (173)
- HIV-1 subtype C syncytium- and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS. (1999) (172)
- Changing Virus‐Host Interactions in the Course of HIV‐1 Infection (1994) (168)
- Relation between changes in cellular load, evolution of viral phenotype, and the clonal composition of virus populations in the course of human immunodeficiency virus type 1 infection. (1996) (162)
- CD39/Adenosine Pathway Is Involved in AIDS Progression (2011) (159)
- Analysis of the Temporal Relationship between Human Immunodeficiency Virus Type 1 Quasispecies in Sequential Blood Samples and Various Organs Obtained at Autopsy (1998) (154)
- Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera (1995) (153)
- Simple determination of human immunodeficiency virus type 1 syncytium-inducing V3 genotype by PCR (1995) (144)
- Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination (2021) (142)
- Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load (2015) (140)
- OKT3 and IL-2 Treatment for Purging of the Latent HIV-1 Reservoir in Vivo Results in Selective Long-Lasting CD4+ T Cell Depletion (2001) (137)
- The effect of plasma drug concentrations on HIV‐1 clearance rate during quadruple drug therapy (1998) (134)
- Low-Level CD4+ T Cell Activation Is Associated with Low Susceptibility to HIV-1 Infection1 (2005) (134)
- Association Study of Common Genetic Variants and HIV-1 Acquisition in 6,300 Infected Cases and 7,200 Controls (2013) (133)
- Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data. (2001) (133)
- Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level (2010) (130)
- The Development of CD4 Binding Site Antibodies during HIV-1 Infection (2012) (129)
- International Network for Comparison of HIV Neutralization Assays: The NeutNet Report (2009) (124)
- Alternative multidrug regimen provides improved suppression of HIV‐1 replication over triple therapy (1998) (122)
- Longitudinal analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte responses: a predominant gag-specific response is associated with nonprogressive infection. (1998) (120)
- An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability (2016) (119)
- Phenotype-associated env gene variation among eight related human immunodeficiency virus type 1 clones: evidence for in vivo recombination and determinants of cytotropism outside the V3 domain (1992) (114)
- The Effect of Trim5 Polymorphisms on the Clinical Course of HIV-1 Infection (2008) (113)
- International Network for Comparison of HIV Neutralization Assays: The NeutNet Report II (2009) (113)
- Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis. (1999) (111)
- Low Immune Activation despite High Levels of Pathogenic Human Immunodeficiency Virus Type 1 Results in Long-Term Asymptomatic Disease (2007) (111)
- Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression (2009) (111)
- Antigen-Specific Antibody Glycosylation Is Regulated via Vaccination (2016) (109)
- Lack of T cell dysfunction and programmed cell death in human immunodeficiency virus type 1-infected chimpanzees correlates with absence of monocytotropic variants. (1993) (109)
- Viral Replication Capacity as a Correlate of HLA B57/B5801-Associated Nonprogressive HIV-1 Infection1 (2007) (108)
- Differential coreceptor expression allows for independent evolution of non-syncytium-inducing and syncytium-inducing HIV-1. (2000) (107)
- Productive HIV‐1 infection of macrophages restricted to the cell fraction with proliferative capacity. (1994) (104)
- Adaptation to promiscuous usage of chemokine receptors is not a prerequisite for human immunodeficiency virus type 1 disease progression. (1999) (103)
- GB virus C coinfection and HIV-1 disease progression: The Amsterdam Cohort Study. (2005) (103)
- CC chemokine receptor 5 cell-surface expression in relation to CC chemokine receptor 5 genotype and the clinical course of HIV-1 infection. (1999) (103)
- Clinical significance of HIV-1 coreceptor usage (2011) (103)
- Evolution of Syncytium-Inducing and Non-Syncytium-Inducing Biological Virus Clones in Relation to Replication Kinetics during the Course of Human Immunodeficiency Virus Type 1 Infection (1998) (102)
- Effects of CCR5-Δ32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection (2003) (102)
- No Treatment versus 24 or 60 Weeks of Antiretroviral Treatment during Primary HIV Infection: The Randomized Primo-SHM Trial (2012) (101)
- Longer V1V2 Region with Increased Number of Potential N-Linked Glycosylation Sites in the HIV-1 Envelope Glycoprotein Protects against HIV-Specific Neutralizing Antibodies (2011) (101)
- Association of HLA-C and HCP5 gene regions with the clinical course of HIV-1 infection (2009) (100)
- Multiple-cohort genetic association study reveals CXCR6 as a new chemokine receptor involved in long-term nonprogression to AIDS. (2010) (91)
- Decreasing sensitivity to RANTES (regulated on activation, normally T cell-expressed and -secreted) neutralization of CC chemokine receptor 5-using, non-syncytium-inducing virus variants in the course of human immunodeficiency virus type 1 infection. (2003) (89)
- CCR5, GPR15, and CXCR6 Are Major Coreceptors of Human Immunodeficiency Virus Type 2 Variants Isolated from Individuals with and without Plasma Viremia (2005) (88)
- In vitro replication kinetics of human immunodeficiency virus type 1 (HIV-1) variants in relation to virus load in long-term survivors of HIV-1 infection. (1998) (88)
- HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy (2008) (88)
- Inactivated Viral Vaccines (2014) (86)
- Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S (2022) (83)
- Rapid Escape from Preserved Cross-Reactive Neutralizing Humoral Immunity without Loss of Viral Fitness in HIV-1-Infected Progressors and Long-Term Nonprogressors (2010) (83)
- Identification of Sequential Viral Escape Mutants Associated with Altered T-Cell Responses in a Human Immunodeficiency Virus Type 1-Infected Individual (2003) (81)
- Isolation and propagation of HIV-1 on peripheral blood mononuclear cells (2008) (79)
- Phenotypic and Genotypic Comparisons of CCR5- and CXCR4-Tropic Human Immunodeficiency Virus Type 1 Biological Clones Isolated from Subtype C-Infected Individuals (2004) (78)
- Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial (2020) (77)
- cis-diamminedichloroplatinum(II)-resistant sublines derived from two human ovarian tumor cell lines. (1988) (77)
- Faculty Opinions recommendation of The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. (2009) (76)
- Role of CCR2 genotype in the clinical course of syncytium-inducing (SI) or non-SI human immunodeficiency virus type 1 infection and in the time to conversion to SI virus variants. (1998) (74)
- Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies (2015) (74)
- Reversal of Human Immunodeficiency Virus Type 1 IIIB to a Neutralization-Resistant Phenotype in an Accidentally Infected Laboratory Worker with a Progressive Clinical Course (2001) (74)
- Presence of the variant mannose‐binding lectin alleles associated with slower progression to AIDS (1998) (73)
- Resistance of surface-dried virus to common disinfection procedures. (2007) (73)
- Rapid CD4+ T-cell turnover in HIV-1 infection: a paradigm revisited. (1998) (71)
- Interference of interleukin-10 with human immunodeficiency virus type 1 replication in primary monocyte-derived macrophages (1994) (71)
- Transmission of zidovudine-resistant human immunodeficiency virus type 1 variants following deliberate injection of blood from a patient with AIDS: characteristics and natural history of the virus. (1995) (70)
- Increased Neutralization Sensitivity of Recently Emerged CXCR4-Using Human Immunodeficiency Virus Type 1 Strains Compared to Coexisting CCR5-Using Variants from the Same Patient (2006) (68)
- Longitudinal Analysis of Early HIV-1-Specific Neutralizing Activity in an Elite Neutralizer and in Five Patients Who Developed Cross-Reactive Neutralizing Activity (2011) (67)
- Detection of Inferred CCR5- and CXCR4-Using HIV-1 Variants and Evolutionary Intermediates Using Ultra-Deep Pyrosequencing (2011) (67)
- Strong association between failure of T cell homeostasis and the syncytium-inducing phenotype among HIV-1-infected men in the Amsterdam Cohort Study (2000) (66)
- Increased in vitro cytopathicity of CC chemokine receptor 5-restricted human immunodeficiency virus type 1 primary isolates correlates with a progressive clinical course of infection. (2003) (66)
- Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons. (2013) (66)
- Diminished Human Immunodeficiency Virus Type 1 Reverse Transcription and Nuclear Transport in Primary Macrophages Arrested in Early G1 Phase of the Cell Cycle (2000) (66)
- Toxicity and drug exposure in a quadruple drug regimen in HIV–1 infected patients participating in the ADAM study (2000) (65)
- Broader tropism and higher cytopathicity for CD4+ T cells of a syncytium-inducing compared to a non-syncytium-inducing HIV-1 isolate as a mechanism for accelerated CD4+ T cell decline in vivo. (1996) (63)
- Activity of Broadly Neutralizing Antibodies, Including PG9, PG16, and VRC01, against Recently Transmitted Subtype B HIV-1 Variants from Early and Late in the Epidemic (2011) (63)
- Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses (2020) (62)
- No evidence for an effect of the CCR5 delta32/+ and CCR2b 64I/+ mutations on human immunodeficiency virus (HIV)-1 disease progression among HIV-1-infected injecting drug users. (1999) (62)
- A Universal Approach to Optimize the Folding and Stability of Prefusion-Closed HIV-1 Envelope Trimers. (2018) (61)
- Genome-wide association study implicates PARD3B-based AIDS restriction. (2011) (60)
- A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates (2018) (59)
- Genome-wide association studies on HIV susceptibility, pathogenesis and pharmacogenomics (2012) (59)
- HIV-1 macrophage tropism is determined at multiple levels of the viral replication cycle. (1994) (59)
- Macrophage‐tropic HIV‐1 variants: initiators of infection and AIDS pathogenesis? (1994) (55)
- The virucidal spectrum of a high concentration alcohol mixture. (2002) (54)
- Ad35 and Ad26 Vaccine Vectors Induce Potent and Cross-Reactive Antibody and T-Cell Responses to Multiple Filovirus Species (2012) (54)
- Pathogenesis of Primary R5 Human Immunodeficiency Virus Type 1 Clones in SCID-hu Mice (2000) (54)
- Phenotype of HIV-1 lacking a functional nuclear localization signal in matrix protein of gag and Vpr is comparable to wild-type HIV-1 in primary macrophages. (1999) (53)
- Depletion of naive CD4 T cells by CXCR4-using HIV-1 variants occurs mainly through increased T-cell death and activation (2003) (52)
- Recovery of viremic control after superinfection with pathogenic HIV type 1 in a long-term elite controller of HIV type 1 infection. (2008) (51)
- Susceptibility of in vitro stimulated PBMC to infection with NSI HIV-1 is associated with levels of CCR5 expression and beta-chemokine production. (2000) (51)
- Impact of CCR5delta32 host genetic background and disease progression on HIV-1 intrahost evolutionary processes: efficient hypothesis testing through hierarchical phylogenetic models. (2011) (50)
- Cytopathicity of Human Immunodeficiency Virus Type 1 Primary Isolates Depends on Coreceptor Usage and Not Patient Disease Status (2001) (49)
- Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats. (2015) (49)
- Correlates of resistance to HIV-1 infection in homosexual men with high-risk sexual behaviour (2004) (49)
- In Vivo Evolution of X4 Human Immunodeficiency Virus Type 1 Variants in the Natural Course of Infection Coincides with Decreasing Sensitivity to CXCR4 Antagonists (2004) (48)
- Chemokine receptors and the clinical course of HIV-1 infection. (1998) (48)
- Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment☆ (2020) (48)
- Reconstructing the Dynamics of HIV Evolution within Hosts from Serial Deep Sequence Data (2012) (47)
- Potential and limitation of UVC irradiation for the inactivation of pathogens in platelet concentrates (2007) (47)
- Reduced prevalence of the CCR5 delta32 heterozygous genotype in human immunodeficiency virus-infected individuals with AIDS dementia complex. (1999) (46)
- Ad26.COV2.S elicited neutralizing activity against Delta and other SARS-CoV-2 variants of concern (2021) (46)
- HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity (2013) (45)
- Immunogenicity and efficacy of one and two doses of Ad26.COV2.S COVID vaccine in adult and aged NHP (2021) (44)
- Viral safety of C1-inhibitor NF. (2007) (44)
- Adenoviral vector type 26 encoding Zika virus (ZIKV) M-Env antigen induces humoral and cellular immune responses and protects mice and nonhuman primates against ZIKV challenge (2018) (43)
- Donor variation in in vitro HIV-1 susceptibility of monocyte-derived macrophages. (2009) (42)
- Genome-Wide Association Scan in HIV-1-Infected Individuals Identifying Variants Influencing Disease Course (2011) (42)
- PER.C6(®) cells as a serum-free suspension cell platform for the production of high titer poliovirus: a potential low cost of goods option for world supply of inactivated poliovirus vaccine. (2013) (42)
- In vitro replication capacity of HIV-2 variants from long-term aviremic individuals. (2006) (41)
- Highly active antiretroviral therapy with or without mycophenolate mofetil in treatment-naive HIV-1 patients (2004) (41)
- Emergence of syncytium-inducing human immunodeficiency virus type 1 variants coincides with a transient increase in viral RNA level and is an independent predictor for progression to AIDS. (1998) (39)
- Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine with an Adenovirus 26 Vector Encoding Pre-Fusion F (Ad26.RSV.preF) in adults 60 years and older. (2020) (39)
- The presence of the Trim5α escape mutation H87Q in the capsid of late stage HIV-1 variants is preceded by a prolonged asymptomatic infection phase (2007) (38)
- Mechanism of anti-HIV activity of negatively charged albumins: biomolecular interaction with the HIV-1 envelope protein gp120. (1996) (38)
- Infectious Cellular Load in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Individuals and Susceptibility of Peripheral Blood Mononuclear Cells from Their Exposed Partners to Non-Syncytium-Inducing HIV-1 as Major Determinants for HIV-1 Transmission in Homosexual Couples (1998) (38)
- Viro‐immunological studies in acute HIV‐1 infection (1994) (38)
- Comparison of Human Immunodeficiency Virus Type 1 Tropism Profiles in Clinical Samples by the Trofile and MT-2 Assays (2009) (38)
- Genome-Wide Association Study Identifies Single Nucleotide Polymorphism in DYRK1A Associated with Replication of HIV-1 in Monocyte-Derived Macrophages (2011) (38)
- Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectively. (1997) (37)
- Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease (2021) (37)
- Increased Sensitivity to CD4 Binding Site-Directed Neutralization following In Vitro Propagation on Primary Lymphocytes of a Neutralization-Resistant Human Immunodeficiency Virus IIIB Strain Isolated from an Accidentally Infected Laboratory Worker (2004) (36)
- Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques (2021) (36)
- Screening Low-Frequency SNPS From Genome-Wide Association Study Reveals a New Risk Allele for Progression to AIDS (2011) (36)
- The effecT of TrIm 5 PolymorPhIsms on The clInIcal course of hIV-1 InfecTIon (2011) (36)
- Susceptibility of Recently Transmitted Subtype B Human Immunodeficiency Virus Type 1 Variants to Broadly Neutralizing Antibodies (2007) (35)
- Characteristics of primary infection of a European human immunodeficiency virus type 1 clade B isolate in chimpanzees. (1998) (35)
- Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption (2020) (34)
- Differential tropism of clinical HIV-1 isolates for primary monocytes and promonocytic cell lines. (1992) (34)
- Cross-reactive broadly neutralizing antibodies: timing is everything (2012) (34)
- Cell turnover and cell tropism in HIV-1 infection. (2002) (34)
- Cytopathic Effects of Non-Syncytium-Inducing and Syncytium-Inducing Human Immunodeficiency Virus Type 1 Variants on Different CD4+-T-Cell Subsets Are Determined Only by Coreceptor Expression (2001) (34)
- Induction of monocyte proliferation and HIV expression by IL-3 does not interfere with anti-viral activity of zidovudine. (1990) (34)
- Natural controlled HIV infection: preserved HIV-specific immunity despite undetectable replication competent virus. (2005) (33)
- HIV-1 seroreversion in an HIV-1-seropositive patient treated during acute infection with highly active antiretroviral therapy and mycophenolate mofetil. (2004) (33)
- Early viral load and CD4+ T cell count, but not percentage of CCR5+ or CXCR4+ CD4+ T cells, are associated with R5-to-X4 HIV type 1 virus evolution. (2003) (33)
- Equal levels of gp120 retention and neutralization resistance of phenotypically distinct primary human immunodeficiency virus type 1 variants upon soluble CD4 treatment (1995) (33)
- A nonprogressive clinical course in HIV-infected individuals expressing human leukocyte antigen B57/5801 is associated with preserved CD8+ T lymphocyte responsiveness to the HW9 epitope in Nef. (2008) (32)
- CTL escape and increased viremia irrespective of HIV-specific CD4+ T-helper responses in two HIV-infected individuals. (2006) (32)
- Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study (2021) (32)
- Virus Validation of PH 4-treated Human Immunoglobulin Produced by the Cohn Fractionation Process (1998) (32)
- Molecular Evolution of Human Immunodeficiency Virus Type 1 upon Transmission between Human Leukocyte Antigen Disparate Donor-Recipient Pairs (2008) (32)
- Evolution of R5 and X4 human immunodeficiency virus type 1 gag sequences in vivo: evidence for recombination. (2003) (31)
- No difference in in vitro susceptibility to HIV type 1 between high-risk HIV-negative Ethiopian commercial sex workers and low-risk control subjects. (2001) (31)
- Naturally HIV-1 seroconverters with lowest viral load have best prognosis, but in time lose control of viraemia. (2002) (31)
- CC-chemokine receptor variants, SDF-1 polymorphism, and disease progression in 720 HIV-infected patients. SEROCO Cohort. Amsterdam Cohort Studies on AIDS. (1999) (31)
- Temporal relationship between elongation of the HIV type 1 glycoprotein 120 V2 domain and the conversion toward a syncytium-inducing phenotype. (1995) (31)
- Comparison of multiple adjuvants on the stability and immunogenicity of a clade C HIV-1 gp140 trimer. (2014) (31)
- Low-Dose Ad26.COV2.S Protection Against SARS-CoV-2 Challenge in Rhesus Macaques (2021) (30)
- CC Chemokine Receptor 5 Δ32 and CC Chemokine Receptor 2 64I Polymorphisms Do Not Influence the Virologic and Immunologic Response to Antiretroviral Combination Therapy in Human Immunodeficiency Virus Type 1–Infected Patients (2002) (30)
- First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector (2018) (29)
- Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate (2020) (29)
- Inhibition of HIV-1 IIIB and clinical isolates by human parotid, submandibular, sublingual and palatine saliva. (2002) (29)
- Effects of HIV‐1 Tat protein on human T cell proliferation (1992) (28)
- Genetic composition of replication competent clonal HIV-1 variants isolated from peripheral blood mononuclear cells (PBMC), HIV-1 proviral DNA from PBMC and HIV-1 RNA in serum in the course of HIV-1 infection. (2010) (28)
- Virulent HIV strains? (1993) (28)
- Loss of HIV-1-derived cytotoxic T lymphocyte epitopes restricted by protective HLA-B alleles during the HIV-1 epidemic (2011) (28)
- Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infection. (2009) (28)
- Safety and Immunogenicity of the Ad26.RSV.preF Investigational Vaccine Coadministered With an Influenza Vaccine in Older Adults. (2020) (27)
- Association between an interleukin-4 promoter polymorphism and the acquisition of CXCR4 using HIV-1 variants (2003) (27)
- Immunity elicited by natural infection or Ad26.COV2.S vaccination protects hamsters against SARS-CoV-2 variants of concern (2021) (27)
- Temporal relationship between human immunodeficiency virus type 1 RNA levels in serum and cellular infectious load in peripheral blood. (1997) (27)
- Escape from autologous humoral immunity of HIV-1 is not associated with a decrease in replicative capacity. (2010) (26)
- Genome-Wide Association Study on the Development of Cross-Reactive Neutralizing Antibodies in HIV-1 Infected Individuals (2013) (26)
- HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds (2016) (26)
- Multicohort genomewide association study reveals a new signal of protection against HIV-1 acquisition. (2012) (26)
- Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study (2020) (25)
- Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques (2021) (25)
- R5 Strains of Human Immunodeficiency Virus Type 1 from Rapid Progressors Lacking X4 Strains Do Not Possess X4-Type Pathogenicity in Human Thymus (1999) (24)
- Early development of broadly reactive HIV-1 neutralizing activity in elite neutralizers (2014) (24)
- Escape of human immunodeficiency virus type 1 from broadly neutralizing antibodies is not associated with a reduction of viral replicative capacity in vitro. (2007) (24)
- Low Levels of Human Immunodeficiency Virus Type 1 DNA in High-Risk Seronegative Men (2005) (24)
- Envelope V2 configuration and HIV-1 phenotype: clarification. (1995) (24)
- Sensitivity of Primary R5 HIV-1 to Inhibition by Rantes Correlates with Sensitivity to Small-Molecule R5 Inhibitors (2005) (23)
- R5 Human Immunodeficiency Virus Type 1 Infection of Fetal Thymic Organ Culture Induces Cytokine and CCR5 Expression (2005) (23)
- Changes in cellular virus load and zidovudine resistance of syncytium-inducing and non-syncytium-inducing human immunodeficiency virus populations under zidovudine pressure: a clonal analysis. (1996) (23)
- Causal Pathways of the Effects of Age and the CCR5-Δ32, CCR2-64I, and SDF-1 3′A Alleles on AIDS Development (2005) (22)
- A vaccine-induced gene expression signature correlates with protection against SIV and HIV in multiple trials (2019) (22)
- Cold-Adapted Viral Attenuation (CAVA): Highly Temperature Sensitive Polioviruses as Novel Vaccine Strains for a Next Generation Inactivated Poliovirus Vaccine (2016) (22)
- Absence of HIV-1 superinfection 1 year after infection between 1985 and 1997 coincides with a reduction in sexual risk behavior in the seroincident Amsterdam cohort of homosexual men. (2010) (22)
- Durability of antibody responses elicited by a single dose of Ad26.COV2.S and substantial increase following late boosting (2021) (22)
- A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti–Zika Virus Vaccine (2021) (22)
- Proliferation-dependent replication in primary macrophages of macrophage-tropic HIV type 1 variants. (1998) (22)
- Slower decline of plasma HIV-1 RNA following highly suppressive antiretroviral therapy in primary compared with chronic infection (2000) (21)
- Prediction of Residual Time to AIDS and Death Based on Markers and Cofactors (2003) (21)
- Adenovector 26 encoded prefusion conformation stabilized RSV-F protein induces long-lasting Th1-biased immunity in neonatal mice (2020) (21)
- Comparative pharmacokinetic, immunologic and hematologic studies on the anti-HIV-1/2 compounds aconitylated and succinylated HSA. (1996) (21)
- Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19 (2021) (20)
- Kinetics of immune functions and virus replication during HIV-1 infection. (1997) (20)
- Lack of evidence for an association between a polymorphism in CX3CR1 and the clinical course of HIV infection or virus phenotype evolution. (2003) (20)
- Impact of host cell variation on the neutralization of HIV-1 in vitro (2009) (19)
- Virus validation of pH 4-treated human immunoglobulin products produced by the Cohn fractionation process. (1998) (19)
- High prevalence of neutralizing activity against multiple unrelated human immunodeficiency virus type 1 (HIV-1) subtype B variants in sera from HIV-1 subtype B-infected individuals: evidence for subtype-specific rather than strain-specific neutralizing activity. (2010) (19)
- Low incidence of HIV-1 superinfection even after episodes of unsafe sexual behavior of homosexual men in the Amsterdam Cohort Studies on HIV Infection and AIDS. (2011) (19)
- Early replication steps but not cell type-specific signalling of the viral long terminal repeat determine HIV-1 monocytotropism. (1993) (19)
- Comparison of in vivo and in vitro evolution of CCR5 to CXCR4 coreceptor use of primary human immunodeficiency virus type 1 variants. (2011) (19)
- HIV-1 Replication Fitness of HLA-B*57/58:01 CTL Escape Variants Is Restored by the Accumulation of Compensatory Mutations in Gag (2013) (19)
- Immunization with Recombinant HLA Classes I and II, HIV-1 gp140, and SIV p27 Elicits Protection against Heterologous SHIV Infection in Rhesus Macaques (2011) (18)
- Coronavirus-Specific Antibody Cross Reactivity in Rhesus Macaques following SARS-CoV-2 Vaccination and Infection (2021) (18)
- Time-measured phylogenies of gag, pol and env sequence data reveal the direction and time interval of HIV-1 transmission (2011) (17)
- SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaques (2021) (17)
- Adenovirus based HPV L2 vaccine induces broad cross-reactive humoral immune responses. (2018) (17)
- Analysis of CD8+ T lymphocyte-mediated nonlytic suppression of autologous and heterologous primary human immunodeficiency virus type 1 isolates. (1997) (17)
- Neutralizing antibodies elicited by the Ad26.COV2.S COVID-19 vaccine show reduced activity against 501Y.V2 (B.1.351), despite protection against severe disease by this variant (2021) (17)
- Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22). (2020) (16)
- Both R5 and X4 Human Immunodeficiency Virus Type 1 Variants Persist during Prolonged Therapy with Five Antiretroviral Drugs (2002) (16)
- Adenovectors encoding RSV-F protein induce durable and mucosal immunity in macaques after two intramuscular administrations (2019) (16)
- Completion of nucleotide sequences of non-syncytium-inducing and syncytium-inducing HIV type 1 variants isolated from the same patient. (1995) (16)
- Mini-hemagglutinin vaccination induces cross-reactive antibodies in pre-exposed NHP that protect mice against lethal influenza challenge (2018) (16)
- Development of a replication‐deficient adenoviral vector‐based vaccine candidate for the interception of HPV16‐ and HPV18‐induced infections and disease (2017) (16)
- Efficient inhibition of both syncytium‐inducing and non‐syncytium‐inducing wild‐type HIV‐1 by lamivudine in vivo (1998) (15)
- IL4 and IL10 as potent inhibitors of HIV1 replication in macrophages in vitro: a role for cytokines in the in vivo virus host range? (1994) (15)
- The Role of Innate APOBEC3G and Adaptive AID Immune Responses in HLA-HIV/SIV Immunized SHIV Infected Macaques (2012) (15)
- Single Nucleotide Polymorphism in Gene Encoding Transcription Factor Prep1 Is Associated with HIV-1-Associated Dementia (2012) (15)
- HIV tropism and CD4+ T-cell depletion (2002) (15)
- Immunization with recombinant macaque major histocompatibility complex class I and II and human immunodeficiency virus gp140 inhibits simian-human immunodeficiency virus infection in macaques. (2012) (15)
- Rising HIV-1 viral load set point at a population level coincides with a fading impact of host genetic factors on HIV-1 control (2011) (15)
- Evolution of Human Immunodeficiency Virus Type 1 in a Patient with Cross-Reactive Neutralizing Activity in Serum (2011) (14)
- Production of high titer attenuated poliovirus strains on the serum-free PER.C6(®) cell culture platform for the generation of safe and affordable next generation IPV. (2015) (14)
- Evidence for a post-entry barrier to R5 HIV-1 infection of CD4 memory T cells (2001) (14)
- Selected HIV-1 Env Trimeric Formulations Act as Potent Immunogens in a Rabbit Vaccination Model (2013) (14)
- Antigen capsid-display on human adenovirus 35 via pIX fusion is a potent vaccine platform (2017) (14)
- Conversion rate towards a syncytium inducing (SI) phenotype during different stages of HIV infection and prognostic value of SI phenotype for survival after aids diagnoses (1997) (13)
- The ADAM study continued: maintenance therapy after 50 weeks of induction therapy. (2001) (13)
- Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial (2022) (13)
- Evaluation of pre-screening methods for the identification of HIV-1 superinfection. (2010) (13)
- Increased Neutralization Sensitivity and Reduced Replicative Capacity of Human Immunodeficiency Virus Type 1 after Short-Term In Vivo or In Vitro Passage through Chimpanzees (2000) (13)
- Persistence of Viral HLA-DR- CD4 T-Cell Reservoir during Prolonged Treatment of HIV-1 Infection with a Five-Drug Regimen (2002) (13)
- No Selection for CCR5 Coreceptor Usage during Parenteral Transmission of Macrophagetropic Syncytium-Inducing Human Immunodeficiency Virus Type 1 (2001) (13)
- Immune Correlates Analysis of a Single Ad26.COV2.S Dose in the ENSEMBLE COVID-19 Vaccine Efficacy Clinical Trial (2022) (13)
- The evolution of human immunodeficiency virus type-1 (HIV-1) envelope molecular properties and coreceptor use at all stages of infection in an HIV-1 donor-recipient pair. (2012) (13)
- Biological and Molecular Aspects of HIV-1 Coreceptor Usage (2003) (13)
- The History of HIV-1 Biological Phenotypes Past , Present and Future (1998) (12)
- Neutralizing Antibody Responses Induced by HIV-1 Envelope Glycoprotein SOSIP Trimers Derived from Elite Neutralizers (2020) (12)
- Correction: Antigen-Specific Antibody Glycosylation Is Regulated via Vaccination (2016) (12)
- Emergence of monoclonal antibody b12-resistant human immunodeficiency virus type 1 variants during natural infection in the absence of humoral or cellular immune pressure. (2010) (12)
- Characterisation of long-term non-progression of HIV-1 infection after seroconversion: a cohort study. (2014) (11)
- T cell line passage can select for pre-existing neutralization-sensitive variants from the quasispecies of primary human immunodeficiency virus type-1 isolates. (2007) (11)
- Potent inhibition of replication of primary HIV type 1 isolates in peripheral blood lymphocytes by negatively charged human serum albumins. (1997) (11)
- Host Genetic Factors in the Clinical Course of HIV-1 Infection: Chemokines and Chemokine Receptors (2002) (11)
- Similar Epitope Specificities of IgG and IgA Antibodies Elicited by Ad26 Vector Prime, Env Protein Boost Immunizations in Rhesus Monkeys (2018) (11)
- A Phylogenetic Analysis of Human Immunodeficiency Virus Type 1 Sequences in Kiev: Findings Among Key Populations (2017) (11)
- CC chemokine receptor 5 delta32 and CC chemokine receptor 2 64I polymorphisms do not influence the virologic and immunologic response to antiretroviral combination therapy in human immunodeficiency virus type 1-infected patients. (2002) (11)
- Polymorphism in HIV-1 dependency factor PDE8A affects mRNA level and HIV-1 replication in primary macrophages. (2011) (11)
- The Neutralizing Antibody Response in an Individual with Triple HIV-1 Infection Remains Directed at the First Infecting Subtype. (2016) (10)
- Low level of HIV-1 evolution after transmission from mother to child (2014) (10)
- Determination of co-receptor usage of HIV-1. (2005) (10)
- Adenovectors encoding RSV-F protein induce durable and mucosal immunity in macaques after two intramuscular administrations (2019) (10)
- Identification of Genes Whose Expression Profile Is Associated with Non-Progression towards AIDS Using eQTLs (2015) (10)
- Intravenous immunoglobulin (IVIG) treatment for modulation of immune activation in human immunodeficiency virus type 1 infected therapy-naive individuals. (2007) (10)
- Isolation, propagation, and titration of human immunodeficiency virus type 1 from peripheral blood of infected individuals. (2005) (10)
- Viral and cellular determinants of HIV‐1 replication in macrophages (1996) (10)
- Publisher Correction: Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques (2021) (9)
- A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2–specific immune responses in rhesus macaques (2022) (9)
- Dynamics of the Pool of Infected Resting Cd4 Hla-Dr- T Lymphocytes in Patients Who Started a Triple Class Five-Drug Antiretroviral Regimen During Primary HIV-1 Infection (2002) (9)
- Short communication: No detrimental immunological effects of mycophenolate mofetil and HAART in treatment-naive acute and chronic HIV-1-infected patients. (2005) (9)
- HIV tropism (1993) (9)
- Immunogenicity of one- and two-dose regimens of the Ad26.COV2.S COVID-19 vaccine candidate in adult and aged rhesus macaques (2020) (8)
- CD4 T cell decline following HIV seroconversion in individuals with and without CXCR4-tropic virus (2017) (8)
- HIV-1 envelope diversity 1 year after seroconversion predicts subsequent disease progression (2012) (8)
- HIV-1 Envelope Glycoprotein Resistance to Monoclonal Antibody 2G12 Is Subject-Specific and Context-Dependent in Macaques and Humans (2013) (7)
- Immunogenicity and protective efficacy of adenoviral and subunit RSV vaccines based on stabilized prefusion F protein in pre-clinical models. (2021) (7)
- Antiviral activity of HIV type 1 protease inhibitors nelfinavir and indinavir in vivo is not influenced by P-glycoprotein activity on CD4+ T cells. (2007) (7)
- Brunenders: a partially attenuated historic poliovirus type I vaccine strain. (2015) (7)
- Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials (2022) (7)
- Molecular determinants of human immunodeficiency virus type I phenotype variability (1996) (7)
- Determination of cell tropism of HIV-1. (2005) (7)
- An inactivated poliovirus vaccine using Sabin strains produced on the serum-free PER.C6® cell culture platform is immunogenic and safe in a non-human primate model (2018) (7)
- HIV-1 transmission and viral adaptation to the host (2012) (6)
- The Presence of CXCR4-Using HIV-1 Prior to Start of Antiretroviral Therapy Is an Independent Predictor of Delayed Viral Suppression (2013) (6)
- SARS-CoV-2 binding and neutralizing antibody levels after vaccination with Ad26.COV2.S predict durable protection in rhesus macaques (2021) (6)
- Novel strategy for the selection of human recombinant Fab fragments to membrane proteins from a phage-display library. (2002) (6)
- The Glycan Hole Area of HIV-1 Envelope Trimers Contributes Prominently to the Induction of Autologous Neutralization (2021) (6)
- CCR5-restricted HIV type 2 variants from long-term aviremic individuals are less sensitive to inhibition by beta-chemokines than low pathogenic HIV type 1 variants. (2008) (5)
- Immunogenicity and efficacy of Ad26.COV2.S: An adenoviral vector–based COVID‐19 vaccine (2022) (5)
- A sweet surprise for HIV broadly neutralizing antibodies (2012) (5)
- 902. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of a Single Immunization of Ad26.RSV.preF against RSV Infection in a Viral Challenge Model in Healthy Adults (2019) (5)
- Correlations between HIV-1 clades and HIV-1 antibody neutralization sensitivity: significant for vaccine development? (2010) (5)
- OA06-05. Adaptation of HIV-1 to the human immune system at the population level is driven by protective HLA-B alleles (2009) (5)
- Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial (2022) (5)
- Synthetic virus seeds for improved vaccine safety: Genetic reconstruction of poliovirus seeds for a PER.C6 cell based inactivated poliovirus vaccine. (2015) (4)
- Lower Broadly Neutralizing Antibody Responses in Female Versus Male HIV-1 Infected Injecting Drug Users (2019) (4)
- Differential Characteristics of Cytotoxic T Lymphocytes Restricted by the Protective HLA Alleles B*27 and B*57 in HIV-1 Infection (2014) (4)
- Efficacy and Safety of a Booster Regimen of Ad26.COV2.S Vaccine against Covid-19 (2022) (4)
- Adenovector 26 encoded prefusion conformation stabilized RSV-F protein induces long-lasting Th1-biased immunity in neonatal mice (2020) (4)
- Safety and immunogenicity of a new Sabin inactivated poliovirus vaccine candidate produced on the PER.C6® cell-line: a phase 1 randomized controlled trial in adults (2020) (4)
- P04-18. Comparison of HIV neutralization assays for use in vaccine research and clinical trials, phase II: results from the NeutNet working group (2009) (4)
- Reply to George and to Stapleton et al. Reply on: GB virus C coinfection and HIV-1 disease progression: The Amsterdam Cohort Study J Infect Dis. 2005 Mar 1;191(5):678-85 (2005) (4)
- Ad26.COV2.S-elicited immunity protects against G614 spike variant SARS-CoV-2 infection in Syrian hamsters and does not enhance respiratory disease in challenged animals with breakthrough infection after sub-optimal vaccine dosing (2021) (4)
- Protection against Marburg Virus and Sudan Virus in NHP by an Adenovector-Based Trivalent Vaccine Regimen Is Correlated to Humoral Immune Response Levels (2022) (4)
- Gag sequence variation in a human immunodeficiency virus type 1 transmission cluster influences viral replication fitness. (2013) (3)
- Correction: A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates (2018) (3)
- Probability of N332 glycan occupancy on HIV-1 gp120 modulates sensitivity to broadly neutralizing antibodies (2016) (3)
- Durability and expansion of neutralizing antibody breadth following Ad26.COV2.S vaccination of mice (2022) (3)
- HIV-1 isolation from infected peripheral blood mononuclear cells. (2014) (3)
- Abstracts of papers and posters (2005) (3)
- P04-49 LB. Adaptation of HIV-1 envelope glycoprotein to humoral immunity at a population level (2009) (3)
- Correlation between HIV‐1 seropositivity and prevalence of a γ‐secretase polymorphism in two distinct ethnic populations (2009) (3)
- Reduced Prevalence of the CCR 5 D 32 Heterozygous Genotype in Human Immunodeficiency Virus – Infected Individuals with AIDS Dementia Complex (1999) (3)
- A comparative study between outbred and inbred rat strains for the use in in vivo IPV potency testing. (2018) (3)
- HIV-1 Subtype C Gag-Specific T-Cell Responses in Relation to Human Leukocyte Antigens in a Diverse Population of HIV-Infected Ethiopians (2007) (3)
- Impact of CCR5 Δ32/+ Deletion on Herpes Zoster Among HIV-1-Infected Homosexual Men (2006) (2)
- Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate (2020) (2)
- Immunogenicity of an Ad26-based SARS-CoV-2 Omicron Vaccine in Naïve Mice and SARS-CoV-2 Spike Pre-immune Hamsters (2022) (2)
- Impact of Preexisting Anti–Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine (2022) (2)
- HIV-1 Infection HLA B 57 / B 5801-Associated Nonprogressive Viral Replication Capacity as a Correlate of Kootstra and Hanneke (2007) (2)
- Association of HLA-C and HCP5 gene regions with the clinical course of HIV-1 infection (vol 23, pg 19, 2009) (2010) (2)
- Cross-reactive neutralizing activity in HIV-1 infected injecting drug users (2012) (2)
- Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of age (2022) (2)
- Normalization of the CD4 T cell receptor repertoire after evolution of syncytium-inducing HIV-1 variants. (2000) (2)
- Therapeutic efficacy of combined active and passive immunization in ART-suppressed, SHIV-infected rhesus macaques (2022) (2)
- CC chemokine receptor 5 delta 32 and CC chemokine receptor 2 64 I polymorphisms do not influence the virologic and immunologic response to antiretroviral combination therapy in human immunodeficiency virus type 1-infected patients (2002) (2)
- Biological Properties of HIV-1 and Their Relevance for Aids Pathogenesis (1999) (2)
- Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamsters (2022) (2)
- HIV-1 envelope glycoprotein characteristics that correlate with the development of cross-reactive neutralizing activity in HIV-1 infected individuals (2012) (2)
- No detrimental immunological effects of mycophenolate mofetil and HAART in treatment-naive acute and chronic HIV-1-infected patients (2007) (2)
- AIDS Pathogenesis (2000) (2)
- Neutralizing antibodies elicited in rabbits by patient-derived Env trimer immunization (2012) (1)
- against recently transmitted subtype B HIV-1 variants from early and late in the 2 (2011) (1)
- UvA-DARE ( Digital Academic Repository ) CD 39 / Adenosine Pathway Is Involved in AIDS Progression (2011) (1)
- Viral and Cellular Requirements for HIV-1 Infection in Monocytes1 (1992) (1)
- Chapter 2 Inactivated Viral Vaccines (2017) (1)
- Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques (2022) (1)
- Negatively charged albumins (1999) (1)
- Combination Ad26.RSV.preF/RSV preF protein vaccine induces superior humoral, cellular, and protective immunity compared with individual vaccine components in preclinical models (2022) (1)
- Further studies into the mechanism of interaction of negatively charged human serum albumins with the V3 loop of the HIV-1 envelope protein Gp120 (1995) (1)
- HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity (2013) (1)
- UvA-DARE (Digital Academic Repository) Clinical significance of HIV-1 coreceptor usage (1)
- WITHDRAWN: Loss of control of viremia in HIV-1 seroconverters with best prognosis and lowest viral load at setpoint (2002) (1)
- Peptide inhibition experiments. (2013) (1)
- IL-10 and HIV-1 Replication (1995) (1)
- cif-Diamminedichloroplatinum ( II )-resistant Sublines Derived from Two Human Ovarian Tumor Cell Lines 1 (2006) (1)
- Cytotoxic T lymphocyte responses in HIV-1-infected long-term nonprogressors: lessons for vaccine design (2008) (1)
- Genome-wide association studies on HIV susceptibility, pathogenesis and pharmacogenomics (2012) (1)
- Standardization of HIV Neutralization Assays for Use in Vaccine Research and Clinical Trials: Results from the NeutNet Working Group (2008) (1)
- Proceedings 23rd International Symposium on Controlled Release of Bioactive Materials (1996) (1)
- P04-50 LB. Prevalence of cross-reactive HIV-1 neutralizing activity in HIV-1 infected patients with rapid or slow disease progression (2009) (1)
- RECENT DEVELOPMENT ON RESEARCH IN AIDS PATHOGENESIS (1994) (1)
- mulTI-cohorT GeneTIc assocIaTIon sTudy reVeals cXcr 6 as a new chemokIne recePTor InVolVed In aIds lonG-Term non-ProGressIon (2011) (1)
- Faculty Opinions recommendation of Genome-scale RNAi screen for host factors required for HIV replication. (2008) (0)
- Neutralizing antibodies elicited in rabbits by patient-derived Env trimer immunization (2012) (0)
- P09-14. Emergence of b12 resistant rapidly replication HIV-1 variants during natural infection in the absence of humoral or cellular immune pressure (2009) (0)
- LB7. Ad26.COV2.S-Elicted Neutralizing Activities Against SARS-CoV-2 Variants of Concern in Phase 1/2a and Phase 3 Clinical Trials (2021) (0)
- Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease (2021) (0)
- Replication competent HIV-1 quasispecies obtained via clonal virus isolation from peripheral blood mononuclear cells is genetically highly similar to the contemporaneous HIV-1 quasispecies in plasma (2009) (0)
- Complementary antibody lineages achieve neutralization breadth in an HIV-1 infected elite neutralizer (2022) (0)
- Sequence Variation intheThirdVariable DomainoftheHumanImmunodeficiency Virus Type1gpl20Molecule (1992) (0)
- Interference ofInterleukin-10 withHuman Immunodeficiency VirusType1Replication inPrimary Monocyte- Derived Macrophages (1994) (0)
- Biological Phenotype ofHumanImmunodeficiency VirusType1 Clones atDifferent Stages ofInfection: Progression ofDisease IsAssociated with a Shift fromMonocytotropic to T-Cell-Tropic VirusPopulations (1992) (0)
- Negatively charged human serum albumins as inhibitors of HIV-1 replication: mechanism of action, in vitro activity against distinct HIV-1 isolates and in vivo efficacy in mice (1997) (0)
- Polymorphism in HIV-1 dependency factor PDE8A affects gene expression and HIV-1 replication in primary macrophages (2011) (0)
- CD4 binding-site antibodies induced by a subtype B HIV-1 envelope trimer (2022) (0)
- CCR5 Δ32 heterozygosity is an early independent progression marker for AIDS in human immunodeficiency virus type 1 infected subjects (1997) (0)
- P07-04. HIV-1 evolution in mother to child transmission and pediatric disease progression (2009) (0)
- Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques (2020) (0)
- HIV-1 envelope characteristics that coincide with the development of cross-reactive neutralizing activity in HIV-1 infected patients (2011) (0)
- Kinetics of HIV-1 specific cytotoxic T lymphocyte responses and viral load in the natural history of HIV-1 infection☆ (1997) (0)
- CONCISE COMMUNICATIONS Reduced Prevalence of the CCR5 D32 Heterozygous Genotype in Human Immunodeficiency Virus-Infected Individuals with AIDS Dementia Complex (1999) (0)
- Mini-hemagglutinin vaccination induces cross-reactive antibodies in pre-exposed NHP that protect mice against lethal influenza challenge (2018) (0)
- Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters (2020) (0)
- Negatively charged human serum albumins as inhibitors of HIV-1 replication: Mechanism of action and in vivo efficacy in mice (1996) (0)
- Sequential use of Ad26-based vaccine regimens in NHP to induce immunity against different disease targets (2022) (0)
- UvA-DARE (Digital Academic Repository) Virus and host determinants of HIV-1 infection and AIDS pathogenesis (2012) (0)
- CHAPTER 5 – Viral and Host Determinants of HIV-1 Disease Progression (2008) (0)
- 2775. Safety and Immunogenicity of a Seasonal Influenza Vaccine and Ad26.RSV.preF Vaccine With and Without Co-Administration: A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study in Adults Aged ≥ 60 Years (2019) (0)
- Adenoviral Type 35 and 26 Vectors with a Bidirectional Expression Cassette in the E1 Region Show an Improved Genetic Stability Profile and Potent Transgene-Specific Immune Response. (2017) (0)
- Negatively charged human serum albumins: Inhibition of replication of primary HIV-1 isolates and biomolecular interaction with gp120 (1994) (0)
- Durability and expansion of neutralizing antibody breadth following Ad26.COV2.S vaccination of mice (2022) (0)
- HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds (2016) (0)
- Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption (2020) (0)
- HIV-1 intra-host evolutionary processes: efficient hypothesis testing through (2010) (0)
- Faculty Opinions recommendation of Characteristics of the earliest cross-neutralizing antibody response to HIV-1. (2011) (0)
- UvA-DARE (Digital Academic Repository) CC chemokine receptor 5 delta32 and CC chemokine receptor 2 64I polymorphisms do not influence the virologic and immunologic response to antiretroviral combination therapy in human immunodeficiency virus type 1-infected patients (2002) (0)
- Faculty Opinions recommendation of Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. (2009) (0)
- RCT Abstract - Ad26.COV2.S immunogenicity in a Phase 2 trial at different booster dose levels and schedule intervals in adults (2021) (0)
- Safety and Immunogenicity of Ad26-vectored HIV Vaccine with Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-uninfected Adults: A Phase 1/2a Study. (2022) (0)
- Faculty Opinions recommendation of Compensatory mutation partially restores fitness and delays reversion of escape mutation within the immunodominant HLA-B*5703-restricted Gag epitope in chronic human immunodeficiency virus type 1 infection. (2007) (0)
- Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola (2022) (0)
- HIV-1 sensitivity to neutralization : biological and molecular studies (2009) (0)
- Cross-reactive neutralizing activity in HIV-1 infected injecting drug users (2012) (0)
- Faculty Opinions recommendation of CD8+ T cells from SIV elite controller macaques recognize Mamu-B*08-bound epitopes and select for widespread viral variation. (2007) (0)
- Faculty Opinions recommendation of HIV-1 adaptation to NK-cell-mediated immune pressure. (2011) (0)
- Combination Ad26.RSV.preF/preF protein vaccine induces superior protective immunity compared with individual vaccine components in preclinical models (2023) (0)
- Broadly reactive neutralizing activity in HIV-1 infected injecting drug users (2016) (0)
- [Amsterdam duration of antiretroviral medication (ADAM)--study: induction-suppression treatment in HIV-I infection, preliminary results]. (1998) (0)
- Comment on Mosier and Sieburg. (1995) (0)
- not interfere with anti-viral activity of zidovudine Induction of monocyte proliferation and HIV expression by IL-3 does (2011) (0)
- Diminished Human Immunodeficiency Virus Type 1 Reverse Transcription and Nuclear Transport in Primary Macrophages Arrested in Early G 1 Phase of the Cell Cycle (2000) (0)
- CoV-2 infection in Syrian hamsters and does not enhance respiratory disease (2021) (0)
- Chapter 9 An HIV elite neutralizer as a blueprint for the induction of neutralizing antibodies (2016) (0)
- HIV-1 envelope glycoprotein characteristics that correlate with the development of cross-reactive neutralizing activity in HIV-1 infected individuals (2012) (0)
- Evolution of Human Immunodeficiency Virus Type 1 in a Patient with Cross-Reactive Neutralizing Activity in Serum (cid:1) (2011) (0)
- Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques (2022) (0)
- The role of polymorphisms in chemokines and chemokine receptors in the clinical course of HIV-1 infection (2004) (0)
- Booster with Ad26.COV2.S or Omicron-adapted vaccine enhanced immunity and efficacy against SARS-CoV-2 Omicron in macaques (2023) (0)
- from Two Human Ovarian Tumor Cell Lines-Diamminedichloroplatinum ( II )-resistant Sublines Derived cis Updated (2006) (0)
- Hanneke Phase of the Cell Cycle 1 in Early G Transport in Primary Macrophages Arrested Type 1 Reverse Transcription and Nuclear Diminished Human Immunodeficiency Virus (2000) (0)
- Deviation from standard dose-response curve by bnMAbs in a U87 target cell assay. (2015) (0)
- Faculty Opinions recommendation of Immune-driven recombination and loss of control after HIV superinfection. (2008) (0)
- envGeneVariation amongEight Related HumanImmunodeficiency VirusType1Clones: Evidence forInVivoRecombination andDeterminants of Cytotropism outside theV3Domain (1992) (0)
- PP 8.6 – 00089 Ad26/MVA Mosaic vaccine induced antibody responses with limited cross-reactivity to CRF01_AE infections (2022) (0)
- CCR5 Genotype and the Clinical Course of HIV-1 Infection (1998) (0)
- Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamsters (2022) (0)
- P19-08. Immunisation with recombinant HLA class I and II, HIV-1gp140 and SIVp27 antigens elicits protection against SHIV-SF162P4 infection in rhesus macaques (2009) (0)
- Use of Immunological and Viral Parameters to Predict Progression of HIV Infection During Natural Course and Antiretroviral Treatment (1997) (0)
- P19-20. Allogeneic stimulation of the anti-viral APOBEC3G in human CD4+ T cells and prevention of SHIV infectivity in macaques immunized with HLA antigens (2009) (0)
- Abstracts of papers clinical pharmacological meeting (2005) (0)
- Dissecting the humoral antibody specificity in relation to virus evolution in pediatric HIV infection (2008) (0)
- UvA-DARE ( Digital Academic Repository ) Detection of inferred CCR 5-and CXCR 4-using HIV-1 variants and evolutionary intermediates using ultra-deep pyrosequencing (2011) (0)
- Evolution of CCR5 using human immunodeficiency virus type 1 in relation to CCR5∆32 host genetic background (2009) (0)
- Booster vaccination with Ad26.COV2.S or an Omicron-adapted vaccine in pre-immune hamsters protects against Omicron BA.2 (2023) (0)
- Faculty Opinions recommendation of R5X4 viruses are evolutionary, functional, and antigenic intermediates in the pathway of a simian-human immunodeficiency virus coreceptor switch. (2008) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With H Schuitemaker?
H Schuitemaker is affiliated with the following schools:
